References
- Christensen PA, Olsen RJ, Long SW, et al. Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with Coronavirus disease 2019 caused by the omicron variant of severe acute Respiratory syndrome Coronavirus 2 in Houston, Texas. Am J Pathol. 2022;192:642–652.
- Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467–484. e15.
- Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022;198:105252.
- Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron Subvariant BA.2. N Engl J Med. 2022;386:1475–1477.
- Xie Y, Yin W, Zhang Y, et al. Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2. Cell Res. 2021;31:1212–1214.
- Qian H-J, Wang Y, Zhang M-Q, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. Acta Pharmacol Sin. 2022. doi:10.1038/s41401-022-00895-6.
- COVID-19 map in China. https://voice.baidu.com/act/newpneumonia/newpneumonia/?from = osari_aladin_banner&city = %E4%B8%8A%E6%B5%B7-%E4%B8%8A%E6%B5%B7 (Accessed 23 Apr 2022).
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054–1062.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395:1569–1578.
- Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of Remdesivir vs standard care on Clinical status at 11 days in patients With moderate COVID-19: A randomized clinical trial. JAMA. 2020;324:1048–1057.
- Commissioner O of the FDA Approves First Treatment for COVID-19. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19 (accessed 23 Apr2022); 2020.
- Mahase E. COVID-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. Br Med J. 2021;375:n2713.
- Jayk Bernal A, da Silva MM G, Musungaie DB, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386:509–520.
- Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021. doi:10.1038/s41586-021-04385-3.
- Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, Nonhospitalized adults with COVID-19. N Engl J Med. 2022;386:1397–1408.
- Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428–430.
- Ekpanyapong S, Bunchorntavakul C, Reddy KR. COVID-19 and the liver: lessons learnt from the EAST and the WEST, A year later. J Viral Hepat. 2022;29:4–20.